ERBB2 and cancer: In addition, immunoconjugates binding a positive regulator of the alternative pathway (FHR4) and the HER2 cancer antigen have been shown to induce complement-dependent cytotoxicity to HER2-expressing tumor cells more efficiently than anti-HER2 Abs (30).